A new preliminary study published in Nature suggests that COVID-19 vaccines might actually boost the immune system to make ...
Arcturus Therapeutics (ARCT) stock falls as Citi downgrades the company following weak mid-stage trial data for its cystic ...
Helping certain genetic information travel to specific parts of nerve cells can ease motor symptoms in SMA, a study in mice ...
PreliminaryResultsYield43%OverallResponseRates(viaRECIST)intheEfficacyPopulationDataDemonstrateREM-422,theFirst-in-ClassSmallMoleculeMYBmRNADegrad ...
Arcturus Therapeutics Holdings Inc. faces a solid cash runway into 2028, pipeline setbacks, and risk/reward profile. Learn ...
Despite showing no meaningful benefit on lung function, Arcturus’ mRNA therapy ARCT-032 reduced mucus volume in patients with ...
Arcturus stock drops on interim Phase 2 results for ARCT-032, showing promising mucus reduction in cystic fibrosis patients ...
Arcturus Therapeutics shares plunged 56% after Phase 2 cystic fibrosis trial data showed no meaningful lung function ...
An international team led by Monash University researchers has uncovered the genetic code governing the way genetic mutations affect mRNA and result in disease.
Lung cancer and melanoma patients immunized with this formula doubled their chances of surviving three years, according to a ...
The ability to correct disease-causing genetic mistakes using genome editors holds great promise in medicine, but it is not without risk. When this type of "genetic surgery" is performed on DNA, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback